Bookmark and Share

Soren M Bentzen
View Curriculum Vitae 

Soren M Bentzen Ph.D., D.M.Sc.

Academic Title: Professor
Primary Appointment: Epidemiology & Public Health
Secondary Appointments: Radiation Oncology
Administrative Title: Division Director, Biostatistics And Bioinformatics
Additional Title(s): Director of the UMGCC Biostatistics Shared Service
sbentzen@som.umaryland.edu
Location: HH 109D
Phone: 410-706-8506
Fax: 410-706-8548

Personal History:

Søren M. Bentzen, MSc, PhD, DMSc, Professor, Director of the Biostatistics Shared Service, University of Maryland Greenebaum Cancer Center, and Director of the Division of Biostatistics and Bioinformatics, Department of Epidemiology and Public Health, University of Maryland School of Medicine since 2013. Dr. Bentzen is also an Adjunct Professor of Radiobiology and Medical Physics, University of Copenhagen, Denmark. His previous appointments include MD Anderson Cancer Center (1987-1988), Danish Cancer Society/Aarhus University (1988-1997), Gray Laboratory/Mount Vernon Hospital, London (1998-2004), and University of Wisconsin School of Medicine and Public Health (2005-2013) where he was a professor of Human Oncology and held affiliate faculty positions in the departments of Biostatistics & Medical Informatics and in Medical Physics.

Dr. Bentzen received a MSc in physics and mathematics (1981), a PhD in medical image analysis (1986), and a DMSc (doctor of medical science) in quantitative clinical radiobiology (1994), all from Aarhus University, Denmark. He has published >370 original papers and book chapters, and has presented >300 invited lectures. He currently serves on 10 international cancer journal editorial boards. His research has been recognized by 24 awards and honors, including the ESTRO Breuer Gold Medal (2003), the MD Anderson Distinguished Alumnus Award (2008), and Honorary Life Memberships of the Association of Radiation Oncologists of India (2008) and the Belgian Society for Therapeutic Radiology and Oncology (2009). He held an Honorary Professorship at University College London (2000-2005) and was a Visiting Statistician to the Medical Research Council Clinical Trials Office, London, UK (1998-2004).

Dr. Bentzen is currently the principal investigator of a randomized controlled phase III trial of resource sparing radiation therapy for locally-advanced squamous cell carcinoma of the head and neck, sponsored by the International Atomic Energy Agency; member of the Previously-untreated Locally Advanced Disease Task Force of the Head and Neck Cancer Steering Committee of the National Cancer Institute (NCI); founding member of the Steering Committee of the International Radiogenomics Consortium; member of the UICC Global Task Force on Radiotherapy for Cancer Control; member of the Board of Directors of the International Commission on Radiation Units; member of the Steering Committee of PENTEC (PEdiatric Normal Tissue Effects in the Clinic) group. He was one of the leaders of the QUANTEC (Quantitative Analyses of Normal Tissue Effects in the Clinic) initiative (2007-2010) and member of the ASTRO Task Force to develop an evidence-based guideline on the appropriate fractionation for whole breast irradiation (2009-2010). He has served as chair or member of 17 (seven currently active) Independent Data and Safety Monitoring Committees or Trial Steering Committees. He is co-chair for Translational Research for two open RTOG phase III trials.

His main research interests include bioeffect modeling; biomathematics; applied biostatistics; clinical trial design; evidence-based medicine; late effects of radiotherapy; clinical radiobiology; integration of data from genomics, proteomics, and molecular imaging into novel therapeutic strategies.


Honors & Awards:

  • 2013 - International KFJ Research Award, Rigshospitalet, University of Copenhagen, Denmark
  • 2011 - 1st James Oleson Visiting Professorship, Duke University, Durham, NC, USA
  • 2011 - Royal Australian and New Zealand College of Radiologists, Keynote Lecturer, Melbourne, VIC, Australia
  • 2011 - Douglas Lea Lecture, Institute of Physics and Engineering in Medicine, UK
  • 2009 - Honorary Life Member, Belgian Society for Therapeutic Radiology and Oncology
  • 2009 - Alan C Burton Lecturer, University of Western Ontario, London, ON, Canada
  • 2009 - Vaeth Lectureship, San Francisco Radiation Oncology Conference, San Francisco, CA, USA
  • 2008 - Honorary Life Member, Association of Radiation Oncologists of India
  • 2008 - Dr. Solomon Padam Singh Oration, Association of Radiation Oncologists of India, Mumbai, India
  • 2008 - Distinguished Alumnus Award, University of Texas, MD Anderson Cancer Center, Houston, TX, USA
  • 2007 - Elis Berven Award Lecture, Swedish Society of Oncology
  • 2006 - Rolf Wideröe Award, Radiumhospitalet, University of Oslo, Norway
  • 2006 - ESTRO-ICTR Translational Research Award, International Conference on Translational Research and Pre-Clinical Strategies in Radio-Oncology, Lugano, Switzerland - - -   
  • 2003 - Acta Oncologica Lectureship, Norwegian Society of Oncology
  • 2003 - Gold Medal (Klaas Breur Medal), European Society for Radiation Oncology (ESTRO)
  • 2003 - Emmanuel van der Schueren Award Lecturer, European School of Oncology
  • 2003 - Institute of Cancer Research Distinguished Lecturer, Sutton, UK
  • 2001 - Allen S. Lichter Lectureship, University of Michigan, Ann Arbor, MI, USA
  • 2001 - Varian Lectureship, Harvard Medical School, Boston, MA, USA
  • 1999 - Royal Australian and New Zealand College of Radiologists Annual Lecturer, Sydney, NSW, Australia
  • 1998 - L.H.Gray Memorial Trust Lecture, Association for Radiation Research, UK
  • 1998 - Clinical Oncology Award, Danish Society for Oncology, Denmark

Publications:

Selected publications from the last 10 years:

Ataman OU, Bentzen SM, Wilson GD, Daley FM, Richman PI, Saunders MI, Dische S. 2004. Molecular biomarkers and site of first recurrence after radiotherapy for head and neck cancer. Eur J Cancer 40:2734-2741.

Buffa FM, Bentzen SM, Daley FM, Dische S, Saunders MI, Richman PI, Wilson GD. 2004. Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. Clin Cancer Res 10:3745-3754.

Trotti A, Bentzen SM. 2004. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol 22:19-22.

Bentzen SM. 2005. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 6:112-117.

Bentzen SM, Atasoy BM, Daley FM, Dische S, Richman PI, Saunders MI, Trott KR, Wilson GD. 2005. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 23:5560-5567.

Bentzen SM, Heeren G, Cottier B, Slotman B, Glimelius B, Lievens Y, van den Bogaert W. 2005. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol 75:355-365.

Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, Terris DJ, Overgaard J. 2005. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77:18-24.

West CM, McKay MJ, Holscher T, Baumann M, Stratford IJ, Bristow RG, Iwakawa M, Imai T, Zingde SM, Anscher MS, Bourhis J, Begg AC, Haustermans K, Bentzen SM, Hendry JH. 2005. Molecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting. Int J Radiat Oncol Biol Phys 62:1264-1273.

Bentzen SM. 2006. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 6:702-713.

Koukourakis MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, Saunders MI, Dische S, Sivridis E, Harris AL. 2006. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24:727-735.

Owen JR, Ashton A, Bliss JM, Homewood J, Harper C, Hanson J, Haviland J, Bentzen SM, Yarnold JR. 2006. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol 7:467-471.

Rustin GJ, Timmers P, Nelstrop A, Shreeves G, Bentzen SM, Baron B, Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Eisenhauer E. 2006. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol 24:45-51.

Bentzen SM, Harari PM, Bernier J. 2007. Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol 4:172-180.

Bentzen SM, Trotti A. 2007. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 25:4096-4103.

Li J, Bentzen SM, Renschler M, Mehta MP. 2007. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 25:1260-1266.

Short SC, Buffa FM, Bourne S, Koritzinsky M, Wouters BG, Bentzen SM. 2007. Dose- and time-dependent changes in gene expression in human glioma cells after low radiation doses. Radiat Res 168:199-208.

Tang PA, Bentzen SM, Chen EX, Siu LL. 2007. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 25:4562-4568.

Bentzen SM. 2008. Radiation oncology health technology assessment: the best is the enemy of the good. Nat Clin Pract Oncol 5:563.

Bentzen SM. 2008. From cellular to high-throughput predictive assays in radiation oncology: challenges and opportunities. Semin Radiat Oncol 18:75-88.

Bentzen SM. 2008. Randomized controlled trials in health technology assessment: overkill or overdue? Radiother Oncol 86:142-147.

Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR. 2008. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 371:1098-1107.

Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR. 2008. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 9:331-341.

Bentzen SM, Buffa FM, Wilson GD. 2008. Multiple biomarker tissue microarrays: bioinformatics and practical approaches. Cancer Metastasis Rev 27:481-494.

Li J, Bentzen SM, Li J, Renschler M, Mehta MP. 2008. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int J Radiat Oncol Biol Phys 71:64-70.

Bernier J, Bentzen SM, Vermorken JB. 2009. Molecular therapy in head and neck oncology. Nat Rev Clin Oncol 6:266-277.

Lee AW, Ng WT, Hung WM, Choi CW, Tung R, Ling YH, Cheng PT, Yau TK, Chang AT, Leung SK, Lee MC, Bentzen SM. 2009. Major late toxicities after conformal radiotherapy for nasopharyngeal carcinoma-patient- and treatment-related risk factors. Int J Radiat Oncol Biol Phys 73:1121-1128.

Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, Ten Haken RK, Yorke ED. 2010. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 76:S3-9.

Bentzen SM, Parliament M, Deasy JO, Dicker A, Curran WJ, Williams JP, Rosenstein BS. 2010. Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects. Int J Radiat Oncol Biol Phys 76:S145-150.

Bentzen SM, Yarnold JR. 2010. Reports of unexpected late side effects of accelerated partial breast irradiation--radiobiological considerations. Int J Radiat Oncol Biol Phys 77:969-973.

Diez P, Vogelius IS, Bentzen SM. 2010. A new method for synthesizing radiation dose-response data from multiple trials applied to prostate cancer. Int J Radiat Oncol Biol Phys 77:1066-1071.

Haviland JS, Yarnold JR, Bentzen SM. 2010. Hypofractionated radiotherapy for breast cancer. N Engl J Med 362:1843-1844.

Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. 2010. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 28:4912-4918.

Pijls-Johannesma M, van Mastrigt G, Hahn SM, De Ruysscher D, Baumert BG, Lammering G, Buijsen J, Bentzen SM, Lievens Y, Kramar A, Lambin P. 2010. A systematic methodology review of phase I radiation dose escalation trials. Radiother Oncol 95:135-141.

Bentzen SM, Gregoire V. 2011. Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. Semin Radiat Oncol 21:101-110.

Smith BD, Bentzen SM, Correa CR, Hahn CA, Hardenbergh PH, Ibbott GS, McCormick B, McQueen JR, Pierce LJ, Powell SN, Recht A, Taghian AG, Vicini FA, White JR, Haffty BG. 2011. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys 81:59-68.

Vogelius IR, Westerly DC, Aznar MC, Cannon GM, Korreman SS, Mackie TR, Mehta MP, Bentzen SM. 2011. Estimated radiation pneumonitis risk after photon versus proton therapy alone or combined with chemotherapy for lung cancer. Acta Oncol 50:772-776.

Vogelius IS, Westerly DC, Cannon GM, Mackie TR, Mehta MP, Sugie C, Bentzen SM. 2011. Intensity-modulated radiotherapy might increase pneumonitis risk relative to three-dimensional conformal radiotherapy in patients receiving combined chemotherapy and radiotherapy: a modeling study of dose dumping. Int J Radiat Oncol Biol Phys 80:893-899.

Watkins Bruner D, James JL, Bryan CJ, Pisansky TM, Rotman M, Corbett T, Speight J, Byhardt R, Sandler H, Bentzen SM, Kachnic L, Berk L. 2011. Randomized, double-blinded, placebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: results of RTOG 0215. J Sex Med 8:1228-1238.

Barnett GC, Coles CE, Elliott RM, Baynes C, Luccarini C, Conroy D, Wilkinson JS, Tyrer J, Misra V, Platte R, Gulliford SL, Sydes MR, Hall E, Bentzen SM, Dearnaley DP, Burnet NG, Pharoah PD, Dunning AM, West CM. 2012. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol 13:65-77.

Barnett GC, Elliott RM, Alsner J, Andreassen CN, Abdelhay O, Burnet NG, Chang-Claude J, Coles CE, Gutierrez-Enriquez S, Fuentes-Raspall MJ, Alonso-Munoz MC, Kerns S, Raabe A, Symonds RP, Seibold P, Talbot CJ, Wenz F, Wilkinson J, Yarnold J, Dunning AM, Rosenstein BS, West CM, Bentzen SM. 2012. Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. Radiother Oncol 105:289-295.

Barnett GC, West CM, Coles CE, Pharoah PD, Talbot CJ, Elliott RM, Tanteles GA, Symonds RP, Wilkinson JS, Dunning AM, Burnet NG, Bentzen SM. 2012. Standardized Total Average Toxicity score: a scale- and grade-independent measure of late radiotherapy toxicity to facilitate pooling of data from different studies. Int J Radiat Oncol Biol Phys 82:1065-1074.

Bekelman JE, Deye JA, Vikram B, Bentzen SM, Bruner D, Curran WJ, Jr., Dignam J, Efstathiou JA, FitzGerald TJ, Hurkmans C, Ibbott GS, Lee JJ, Merchant TE, Michalski J, Palta JR, Simon R, Ten Haken RK, Timmerman R, Tunis S, Coleman CN, Purdy J. 2012. Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys 83:782-790.

Bentzen SM, Dorr W, Gahbauer R, Howell RW, Joiner MC, Jones B, Jones DT, van der Kogel AJ, Wambersie A, Whitmore G. 2012. Bioeffect modeling and equieffective dose concepts in radiation oncology--terminology, quantities and units. Radiother Oncol 105:266-268.

Blomstrand M, Brodin NP, Munck Af Rosenschold P, Vogelius IR, Sanchez Merino G, Kiil-Berthlesen A, Blomgren K, Lannering B, Bentzen SM, Bjork-Eriksson T. 2012. Estimated clinical benefit of protecting neurogenesis in the developing brain during radiation therapy for pediatric medulloblastoma. Neuro Oncol 14:882-889.

Bowen SR, Chappell RJ, Bentzen SM, Deveau MA, Forrest LJ, Jeraj R. 2012. Spatially resolved regression analysis of pre-treatment FDG, FLT and Cu-ATSM PET from post-treatment FDG PET: an exploratory study. Radiother Oncol 105:41-48.

Brodin NP, Vogelius IR, Maraldo MV, Munck af Rosenschold P, Aznar MC, Kiil-Berthelsen A, Nilsson P, Bjork-Eriksson T, Specht L, Bentzen SM. 2012. Life years lost--comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale. Cancer 118:5432-5440.

Vogelius IR, Bentzen SM. 2012. A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol 51:975-983.

Appelt AL, Vogelius IR, Bentzen SM. 2013. Modern hypofractionation schedules for tangential whole breast irradiation decrease the fraction size-corrected dose to the heart. Clin Oncol (R Coll Radiol) 25:147-152.

Brodin NP, Vogelius IR, Bjork-Eriksson T, Munck af Rosenschold P, Bentzen SM. 2013. Modeling freedom from progression for standard-risk medulloblastoma: a mathematical tumor control model with multiple modes of failure. Int J Radiat Oncol Biol Phys 87:422-429.

Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, Choucair A, Fox S, Suh JH, Roberge D, Kavadi V, Bentzen SM, Mehta MP, Watkins-Bruner D. 2013. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 15:1429-1437.

Cannon DM, McHaffie DR, Patel RR, Adkison JB, Das RK, Anderson BD, Geye HM, Bentzen SM, Cannon GM. 2013. Locoregional recurrence following accelerated partial breast irradiation for early-stage invasive breast cancer: significance of estrogen receptor status and other pathological variables. Ann Surg Oncol 20:3446-3452.

Cannon DM, Mehta MP, Adkison JB, Khuntia D, Traynor AM, Tome WA, Chappell RJ, Tolakanahalli R, Mohindra P, Bentzen SM, Cannon GM. 2013. Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol 31:4343-4348.

Hong JC, Kruser TJ, Gondi V, Mohindra P, Cannon DM, Harari PM, Bentzen SM. 2013. Risk of cerebrovascular events in elderly patients after radiation therapy versus surgery for early-stage glottic cancer. Int J Radiat Oncol Biol Phys 87:290-296.

Lawrence YR, Vikram B, Dignam JJ, Chakravarti A, Machtay M, Freidlin B, Takebe N, Curran WJ, Jr., Bentzen SM, Okunieff P, Coleman CN, Dicker AP. 2013. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. J Natl Cancer Inst 105:11-24.

Ronjom MF, Brink C, Bentzen SM, Hegedus L, Overgaard J, Johansen J. 2013. Hypothyroidism after primary radiotherapy for head and neck squamous cell carcinoma: Normal tissue complication probability modeling with latent time correction. Radiother Oncol 109:317-322.

Vogelius IR, Bentzen SM. 2013. Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys 85:89-94.

Vogelius IR, Hakansson K, Due AK, Aznar MC, Berthelsen AK, Kristensen CA, Rasmussen J, Specht L, Bentzen SM. 2013. Failure-probability driven dose painting. Med Phys 40: 081717.

Kerns SL, de Ruysscher D, Andreassen CN, Azria D, Barnett GC, Chang-Claude J, Davidson S, Deasy JO, Dunning AM, Ostrer H, Rosenstein BS, West CM, Bentzen SM. STROGAR - STrengthening the Reporting Of Genetic Association studies in Radiogenomics. Radiother Oncol. 2014 Jan;110(1):182-8.

Brodin NP, Vogelius IR, Björk-Eriksson T, Munck Af Rosenschöld P, Maraldo MV, Aznar MC, Specht L, Bentzen SM. Optimizing the radiation therapy dose prescription for pediatric medulloblastoma: minimizing the life years lost attributable to failure to control the disease and late complication risk. Acta Oncol. 2014 Apr;53(4):462-70.

Haviland JS, A'Hern R, Bentzen SM, Whelan T, Bliss JM. Radiotherapy for breast cancer, the TARGIT-A trial. Lancet. 2014 May 17;383(9930):1716-7.

Barnett GC, Thompson D, Fachal L, Kerns S, Talbot C, Elliott RM, Dorling L, Coles CE, Dearnaley DP, Rosenstein BS, Vega A, Symonds P, Yarnold J, Baynes C, Michailidou K, Dennis J, Tyrer JP, Wilkinson JS, Gómez-Caamaño A, Tanteles GA, Platte R, Mayes R, Conroy D, Maranian M, Luccarini C, Gulliford SL, Sydes MR, Hall E, Haviland J, Misra V, Titley J, Bentzen SM, Pharoah PD, Burnet NG, Dunning AM, West CM. A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. Radiother Oncol. 2014 May;111(2):178-85.

Due AK, Vogelius IR, Aznar MC, Bentzen SM, Berthelsen AK, Korreman SS, Loft A, Kristensen CA, Specht L. Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. Radiother Oncol. 2014 Jun;111(3):360-5.

Brink C, Bernchou U, Bertelsen A, Hansen O, Schytte T, Bentzen SM. Locoregional control of non-small cell lung cancer in relation to automated early assessment of tumor regression on cone beam computed tomography. Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):916-23.

Rasmussen JH, Vogelius IR, Fischer BM, Friborg J, Aznar MC, Persson GF, Håkansson K, Kristensen CA, Bentzen SM, Specht L. Prognostic value of 18F-fludeoxyglucose uptake in 287 patients with head and neck squamous cell carcinoma. Head Neck. 2014 May 7. doi: 10.1002/hed.23745.